Preclinical News and Research

RSS

Patented fibrin-based matrices and tissue may open doors for tissue and organ engineering

Virginia Commonwealth University engineers and scientists have developed and patented a unique technique to grow three-dimensional tissues and organs in a mold made from material the human body naturally uses to repair wounds, potentially eliminating the chance for rejection.

17 Nov 2004

Troponin genes offer new insights to familial heart failure

Mutations in the troponin protein complex may be useful for predicting the course of heart failure due to dilated cardiomyopathy and also for guiding treatment and research, according to a new study in the Nov. 16, 2004 issue of the Journal of the American College of Cardiology.

16 Nov 2004

Lorus Therapeutics allowed Canadian patent to protect anticancer drugs

Lorus Therapeutics today announced that its wholly owned subsidiary, GeneSense Technologies Inc., has been allowed a patent by the Canadian Patent Office entitled "Antitumor Antisense Sequences Directed Against R1 and R2 Components of Ribonucleotide Reductase."

10 Nov 2004

New studies demonstrate efficacy of novel Lipoxin analog in laboratory models of Crohn's disease

Berlex announced today that new laboratory results demonstrate that its modified version of the naturally occurring lipoxin molecule exerts potent anti-inflammatory and immunomodulatory effects in Crohn's disease in vivo models and may provide a promising new oral treatment.

9 Nov 2004

Lipid Sciences' selective delipidation process demonstrates enhanced ability in removing cholesterol from cells

Lipid Sciences announced today that researchers have successfully used the Company's proprietary "selective delipidation" process to create a modified form of HDL ("good cholesterol") that is known to be more effective in reverse cholesterol transport, the body's natural process for removing lipids from arterial plaque.

8 Nov 2004

Celebrex may one day be used to prevent and even treat breast tumors

The anti-inflammatory drug Celebrex, or celecoxib, reduces tumor mass by encouraging cell death and discouraging both cell proliferation and the sprouting of new blood vessels that feed growing tumors, according to a study reported in the November issue of Molecular Cancer Research.

5 Nov 2004

FDA fast tracks investigational anti-cancer drug, phenoxodiol

Marshall Edwards today announced that the U.S. Food and Drug Administration (FDA) has granted the investigational anti-cancer drug, phenoxodiol, Fast Track status for its intended use in patients with recurrent ovarian cancer.

4 Nov 2004

$73 million to tackle infectious diseases such as West Nile virus and influenza

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded 14 contracts totaling more than $73 million to fund the Large-Scale Antibody and T Cell Epitope Discovery Program, an initiative aimed at quickly identifying the regions of selected infectious agents that elicit immune reactions.

1 Nov 2004

Discovery of a number of potent and selective small molecule inhibitors of the hepatitis C (HCV) NS3/4 protease

InterMune announced today the presentation of preclinical data on the discovery and characterization of a number of potent and selective small molecule inhibitors of the hepatitis C (HCV) NS3/4 protease.

1 Nov 2004

FDA approves Nastech vitamin B-12 deficiency nasal spray

Nastech Pharmaceutical Company has announced receipt of an approvable letter from the U.S. Food and Drug Administration (FDA) on Nascobal (Cyanocobalamin, USP) Nasal Spray for the treatment of vitamin B-12 deficiency.

1 Nov 2004

Human Genome Sciences announces agreement with GSK for development of drug to treat diabetes

Human Genome Sciences today announced an agreement with GlaxoSmithKline under which GlaxoSmithKline has acquired exclusive worldwide rights to develop and commercialize Albugon (albumin-glucagon-like peptide-1, GLP-1), a drug currently in late-stage preclinical development by Human Genome Sciences for potential use in the treatment of diabetes.

26 Oct 2004

Ruboxistaurin may reduce vision loss from diabetes-induced eye disease

Eli Lilly and Company's investigational compound ruboxistaurin may reduce vision loss from diabetes-induced eye disease, according to new analyses of previously reported data presented at the 2004 Joint Meeting of the American Academy of Ophthalmology and the European Society of Ophthalmology in New Orleans, La.

26 Oct 2004

Radiotherapy with cetuximab significantly improves disease control and survival in head and neck cancer

Combination treatment using the monoclonal antibody cetuximab, along with high dose radiotherapy in the treatment of patients with loco-regionally advanced squamous cell carcinoma of the head and neck results in significant improvements in both loco-regional control and overall survival, according to Dr Jordi Giralt of Val d'Hebron University Hospital.

26 Oct 2004

The aging American population means that more people are at risk for stroke

A leading stroke researcher says the aging of the American population means that more people are at risk for stroke, and unless new approaches are developed to reduce stroke incidence, it will surpass heart attacks and cancer as the major cause of long-term disability and premature death.

22 Oct 2004

QIMR researchers have received a 5 year grant to develop a vaccine against Group A streptococcus

QIMR researchers have received a 5 year grant from the National Institutes of Health in the USA to develop a vaccine against Group A streptococcus. This extremely prestigious grant makes QIMR one of the most successful recipients of NIH funding in Australia.

18 Oct 2004

MedImmune progresses development of Respiratory Syncytial Virus and Parainfluenza Virus Type-3 vaccines

MedImmune has announced that data from a preclinical study for its lead vaccine candidate to prevent respiratory syncytial virus (RSV) and parainfluenza virus type-3 (PIV-3) has shown a protective immune response against both viruses in animals.

13 Oct 2004

Researchers stimulate the body to repair tissue damaged by peripheral arterial obstructive disease

Duke University Medical Center researchers have shown that they can stimulate the body to produce its own naturally occurring growth factors to promote blood vessel growth into tissue damaged by peripheral arterial obstructive disease (PAOD).

13 Oct 2004

A novel gene therapy strategy may help reduce seizures in adults suffering from epilepsy

Deborah Lin, from the Faculty of Medical and Health Sciences, is investigating the effects of a therapeutic gene transfer in a particular form of epilepsy which affects the brain’s temporal lobe region.

12 Oct 2004

Boosting the blood count in conjunction with radiation therapy doesn't improve survival for head and neck cancer patients

Boosting the blood count – in effect, curing anemia – in conjunction with radiation therapy won't help patients with head and neck cancer fare any better than with radiation alone, says a national study led by Jefferson Medical College researchers.

5 Oct 2004

FDA fast tracks Genaera's drug for the treatment of wet age-related macular degeneration

Genaera Corporation has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to squalamine, an intravenously administered, first in class, small molecule anti-angiogenic drug for the treatment of "wet" age-related macular degeneration (AMD).

4 Oct 2004

Preclinical News and Research

Patented fibrin-based matrices and tissue may open doors for tissue and organ engineering

Troponin genes offer new insights to familial heart failure

Lorus Therapeutics allowed Canadian patent to protect anticancer drugs

New studies demonstrate efficacy of novel Lipoxin analog in laboratory models of Crohn's disease

Lipid Sciences' selective delipidation process demonstrates enhanced ability in removing cholesterol from cells

Celebrex may one day be used to prevent and even treat breast tumors

FDA fast tracks investigational anti-cancer drug, phenoxodiol

$73 million to tackle infectious diseases such as West Nile virus and influenza

Discovery of a number of potent and selective small molecule inhibitors of the hepatitis C (HCV) NS3/4 protease

FDA approves Nastech vitamin B-12 deficiency nasal spray

Human Genome Sciences announces agreement with GSK for development of drug to treat diabetes

Ruboxistaurin may reduce vision loss from diabetes-induced eye disease

Radiotherapy with cetuximab significantly improves disease control and survival in head and neck cancer

The aging American population means that more people are at risk for stroke

QIMR researchers have received a 5 year grant to develop a vaccine against Group A streptococcus

MedImmune progresses development of Respiratory Syncytial Virus and Parainfluenza Virus Type-3 vaccines

Researchers stimulate the body to repair tissue damaged by peripheral arterial obstructive disease

A novel gene therapy strategy may help reduce seizures in adults suffering from epilepsy

Boosting the blood count in conjunction with radiation therapy doesn't improve survival for head and neck cancer patients

FDA fast tracks Genaera's drug for the treatment of wet age-related macular degeneration

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News